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Abstract
Polyomavirus BK (BKV) infects up to 90% of the 
general population. After primary infection, occurring 
early during childhood, a state of non-replicative 
infection is established in the reno-urinary tract, 
without complications for immunocompetent hosts. 
In immunocompromised individuals, particularly 
transplanted patients, asymptomatic BKV viremia and/
or viruria can be observed. Renal grafts may also be 
sources of infection as BKV prefers kidneys rather than 
other solid organs for transplantation such as the liver. 
The mechanism behind the higher incidence of BKV 
infection in kidney transplant patients, compared to liver 
or heart transplantation, is unclear and the prevalence 
of BKV infection in non-renal solid organ transplants 
has not been yet thoroughly investigated. We evaluated 
the prevalence of Polyomavirus BK infection among liver 
transplant recipients. A PubMed search was conducted 
using the terms BKV infection AND liver transplant 
recipients; BKV AND non-renal solid organ transplant*; 
BKV infection AND immunosuppression; the search was 
limited to title/abstract and English-language articles 
published from 2000, to March 2015. Eleven relevant 
studies suggest that the prevalence of BKV viruria and/
or viremia among liver transplant recipients is less than 
that reported in kidney or heart transplant recipients, 
except when chronic kidney disease (CKD) is present 
at the same time. Data also suggest that viruric and 
viremic patients have higher levels of serum creatinine 
than BKV negative patients. Moreover, no specific 
immunosuppressive drugs are associated with the onset 
of BKV nephropathy. The comorbidity of transplantation 
and CKD could play a major role in promoting BKV 
replication.
Key words: BK virus; Polyomavirus BK infection; Liver 
transplantation; Liver transplant recipients
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Core tip: The prevalence of polyomavirus BK (BKV) 
infection among non-renal solid organ transplant 
recipients has been insufficiently investigated. Our 
review suggests that BKV viruria and/or viremia in liver 
transplantation is less prevalent than what has been 
reported in kidney or heart transplants, except when 
renal dysfunction is present. In general, viruric and 
viremic liver transplant patients have higher levels of 
serum creatinine. Therefore, renal dysfunction in liver 
transplantation may be an additional factor causing 
immunologic dysfunction that could make patients 
more susceptible to BKV infection. 
Umbro I, Tinti F, Muiesan P, Mitterhofer AP. Different behaviour 
of BK-virus infection in liver transplant recipients. World J 
Gastroenterol 2016; 22(4): 1532-1540  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i4/1532.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i4.1532
INTRODUCTION
Polyomaviruses are widespread among vertebrates. 
Man is the natural host for BK virus (BKV) also known 
as Polyomavirus hominis 1. The human Polyomavirus 
BK was first isolated in the 1970s[1,2] from the urine 
of a renal transplant patient with ureteric stenosis, 
shedding cytopathically altered cells with atypical 
nuclear morphology[2]. This patient’s initials gave the 
name to the virus. 
BKV GENOME
BKV and JCV are species of Polyomavirus of the family 
Polyomaviridae, which are characterized by a typical 
morphology of non-enveloped virions with icosahedral 
capsids of 45 µm diameter. These capsids enclose 
the viral genome, a small circular double-stranded 
DNA genome of 5300 base pairs coated by host-cell 
histones. The BKV genome shares an overall homology 
of 75% with JCV and can be divided into regulatory, 
early, and late regions[3].
The Polyomavirus genome architecture is conserved 
and encodes only 6 proteins. It consists of the non-
coding control region (NCCR) that contains the origin 
of DNA replication and bidirectional promoters. The 
two early gene proteins, the small and the large 
tumour antigen (LTag), are encoded by the early 
genes. The four late gene proteins, including the 
three viral capsid proteins and the agnoprotein, are 
encoded by the late genes. The LTag is a conserved 
multifunctional regulator of transcription and replication 
of polyomavirus. Rearrangements of the NCCR occur 
with persisting BKV replication increasing replication 
capacity[4,5]. The LTag interacts with proteins of the 
host cell and disrupts its division, collecting factors to 
promote viral DNA replication[6].
After production of proteins constituting the viral 
capsid, the virion is assembled in the nucleus with 
subsequent lysis of the host cell and discharge of the 
viral progeny. As viral antigens are released in the 
host’s circulation a reactive nonspecific inflammatory 
response mounts, followed by a specific immune 
response[1].
BKV EPIDEMIOLOGY
Polyomavirus hominis 1 infects up to 90% of the 
general population[1,7,8]. Primary BKV infection occurs 
early during childhood, in the first decade of life, 
more often at an age of 4-5 years[9]. During the first 
10 years of life, the sero-prevalence reaches 50% 
of the individuals whilst in the adult population it is 
recorded as more than 70% worldwide with exception 
of isolated populations of Asia and South America[7]. 
Immunosuppression, as in the elderly and pregnant 
women, is a known risk factor for an increased 
prevalence of BKV infection.
Natural BKV transmission is likely to occur via the 
respiratory or oro-pharyngeal tracts[1]. The primary 
route of transmission is likely to be via fomites or 
aerosol given the association of primary infection with 
upper respiratory infections[10,11]. Further possible 
routes of BKV transmission are related to semen, blood 
products transfusions and transplantation of organs, in 
particular of the kidney[7,12-15]. 
After primary infection, BKV colonizes the reno-
urinary tract, most likely, via a primary viremia[1,16]. 
Latency is a state of silent infection which is localised 
in urothelial cells and in the tubular epithelium, without 
known complications for the immunocompetent host. 
Other sides of detection of BKV genomes include 
prostatic tissue, ureteric and bladder urothelial, renal 
cortex and medulla[12,16].
Reactivation and asymptomatic shedding in the 
urine of healthy BKV sero-positive immunocompetent 
individuals ranges from 0%-62%[8,17,18]. About 5% 
of healthy individuals intermittently reactivate BKV 
replication with low detectable level of asymptomatic 
viruria[1,13].
In individuals with impaired immune functions, 
particularly after solid organ transplantation (SOT) or 
hematopoietic stem cell transplant (HSCT), asymptomatic 
high-level urinary BKV replication is observed with 
appearance of “decoy cells” in urine cytology and virus 
particles detectable by direct negative staining electron 
microscopy[19-21].
BKV REACTIVATION
High prevalence, latent infection, and asymptomatic 
reactivation of BKV interfere with a straightforward 
knowledge/comprehension of the pathogenic role of 
this virus. Therefore, BKV infection, BKV replication 
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and BKV disease were defined as stated in a previous 
review by Hirsch et al[1]: (1) BKV infection is diagnosed 
by serological evidence of replicative and non-
replicative virus exposure (latency); (2) BKV replication 
is confirmed by demonstration of active or lytic 
infection with multiple modalities. Primary infection 
is diagnosed by isolation of viral genes or products in 
sero-negative individuals. When the BKV replicates in 
sero-positive individuals, this is defined as secondary 
infection. Reinfection is defined by diagnosis of a new 
subtype and reactivation by detection of replication 
of a latent virus; and (3) BKV disease occurs when 
the replicating BKV leads to organ dysfunction and 
failure as shown by tissue disease together with viral 
replication. 
BKV DISEASES
Major symptoms are uncommon and restricted to 
patients with an impairment of immune system. 
The Polyomavirus BK is closely linked to two major 
complications in transplant recipients, polyomavirus 
associated nephropathy (PVAN) in 1%-10% of kidney 
transplant (KT) patients[22-25] and polyomavirus-
associated haemorrhagic cystitis in 5%-15% of HSCT 
patients[26-28]. Both diseases occur only sporadically in 
patients with non-renal SOT (NRSOT) or with inherited, 
acquired or drug-induced immunodeficiency[1,29]. Besides 
these major problems, BKV has been associated with 
other pathologies such as tubulo-interstitial nephritis, 
ureteral stenosis, vasculopathies, pneumonia, hepatitis, 
encephalitis, retinitis, as well as multi-organ failure, 
autoimmune disease and cancer[1,30-33]. 
BKV INFECTION IN LIVER TRANSPLANT 
RECIPIENTS
Polyomavirus BK-associated nephropathy represents 
the most important cause of graft dysfunction after 
KT. Risk factors for PVAN are related to donor, graft, 
virus, recipient characteristics and immunosuppressive 
regimens. 
Renal grafts may also be sources of infection as 
BKV prefers kidneys rather than other solid organs 
for transplantation such as the liver[34]. As suggested 
in literature, BKV is known for its tropism for renal 
epithelial cells. The mechanism by which BKV infection 
incidence is greater in KT compared to heart transplant 
(HT) and liver transplantation (LT) is not clear. It is 
plausible that different viral genome may be passed 
from donors into susceptible recipients with the 
transplanted kidney as a new infection[35-37]. Such 
mechanism would not be open to transplantation of 
different solid organs. Therefore, BKV-specific cytotoxic 
T-lymphocytes would be impotent in eliminating viral 
genome which is thus able to escape the immune 
system causing PVAN[34,36,38]. On the contrary, it seems 
that BKV genome is not able to resist in cells from 
liver and heart, therefore it is unlikely that it could be 
transmitted by these organs. 
BKV reactivation may be allowed by some factors, 
such as inflammation. This could be showed by the 
greater association between BKV infection and KT 
from deceased donors compared to living donor KT, 
probably due to the longer cold ischaemia time[35]. 
Moreover, BKV replication in KT could be related to 
ischaemic injury which occurs during the surgical 
procedure or to kidney graft rejections. 
The immunosuppressive regimens have also been 
suggested to play a key role. Although immunosuppressive 
therapy is administered to all SOT patients, induction 
therapy is more often used in renal transplantation 
and steroids are typically administered for longer time 
in KT compared to LT[37]. The role of steroids in the 
reduction of immune reaction has been demonstrated. 
They may cause T-cells apoptosis and granzyme B 
downregulation. The latter has a pivotal role in granule 
exocytosis used by natural killer and cytotoxic T-cells[39]. 
Furthermore they are able to prevent production and 
normal activity of dendritic cells[40,41]. The impaired 
function of natural killer, dendritic and T-cells related to 
the use of steroids may be associated with the major 
predilection of PVAN for KT patients. Nevertheless, 
immunodepression on its own, could not clarify the 
elevated BKV incidence in KT, since renal transplant 
recipients do not seem to be significantly more 
immunosuppressed than LT and HT recipients[35,42-44]. 
Chronic kidney disease (CKD) occurs in up to half 
cases of NRSOT in the long-term follow-up[45-48] and 
it is associated with a worse prognosis compared to 
patients without CKD[45]. In particular, CKD is very 
common after LT and its cause is often multifactorial, 
though calcineurin-inhibitor nephrotoxicity plays 
a pivotal role. Therefore, among LT patients, pre-
transplant renal function, hepatitis-C virus infection, 
diabetes and older age have been identified as risk 
factors for CKD[45]. In this context, the role of BKV 
infection in the occurrence of CKD has not been 
systematically studied. As renal biopsies are not 
performed in a routine way after NRSOT, unrecognized 
factors such as PVAN could also play a role[49].
RESEARCH
A PubMed search was conducted using the terms 
BKV infection AND liver transplant recipients; BKV 
AND non-renal solid organ transplant*; BKV infection 
AND immunosuppression. Results were limited to 
title/abstract and English-language articles published 
from 2000, to March 2015. From this search, relevant 
articles presenting clinical data on the prevalence of 
BKV infection among liver transplant recipients were 
identified. The PubMed search retrieved 125 articles, 
and these abstracts were screened for relevance. Case 
reports, case series, review articles, and editorials 
were not considered. 
Studies on children and renal transplantation only 
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with BKV viruria, and 3.5 mg/dL in patients with BKV 
viremia. The authors also showed that the association 
between BKV replication and renal function was 
significant in HT patients but not in LT or KT patients. 
Independent factors associated to renal dysfunction 
were renal transplantation, BKV replication, and MMF 
therapy.
In a cross-sectional study by Randhawa et al[52], BKV 
viral load among 103 KT at risk for viral nephropathy 
and 44 LT patients were compared with BKV viral 
load among 23 non-immunosuppressed subjects with 
suspected urinary tract infection. Immunosuppression 
consisted primarily of pre-transplant induction with anti-
CD52 antibody and maintenance on TAC, prednisone 
and MMF. In the KT group, BK viruria was found in 
36 recipients (34.9%), whereas BK viremia was 
showed in 8/103 (7.7%) recipients. Plasma viral 
load was significantly less than urine load in the 
corresponding patients. In LT patients, BKV viruria 
was observed in 7 (15.9%) recipients. No cases of 
BKV viremia were observed in LT recipients. Among 
23 non-immunosuppressed patients, BKV viruria was 
found in 2 (8.7%). Mean BKV urinary viral load in KT 
patients was greater than in LT recipients. Moreover, 
BKV viruria was more common in KT recipients than 
in non-immunosuppressed individuals. The 2 KT 
recipients showing high urinary BKV load had viral 
interstitial nephritis; plasma viral load was available 
for only one of these. In the other cases, renal 
dysfunction was associated to acute cellular rejection, 
calcineurin inhibitors (CNI) toxicity and chronic allograft 
nephropathy.
Razonable et al[53] conducted a longitudinal sur-
veillance study considering epidemiology and clinical 
consequences of BKV infection in 263 SOT patients (121 
LT, 92 KT, 45 HT and 5 kidney-pancreas transplants) 
at high risk of Cytomegalovirus (CMV) disease. BKV 
viremia was found in 32/263 (12.2%) at the median 
time of 100 d after transplantation and 24 of them (75%) 
were KT recipients. Thus, among 92 KT patients, BKV 
viremia incidence was 26%. In most cases BKV DNA 
positivity in the blood was subclinical whereas coexisted 
with clinical or biopsy-proven acute kidney rejection in 
6 patients (25%). Three out of 32 (25%) patients with 
BKV DNAemia were HT (6.7%) and 5 were LT (4.1%) 
recipients. All HT recipients and 1 LT recipient had BKV 
DNAemia after treatment for acute graft rejection. 
Notably none of these patients had renal dysfunction 
within a month before or 1 mo and 1 year after BKV 
DNAemia. Seventeen of 32 (53%) BKV DNAemic 
patients developed CMV viremia, 10 of whom (32%) 
had CMV disease, compared to 16% of BKV DNAemic 
recipients.
In the prospective, single-centre, cross-sectional 
study conducted by Barton et al[54], 34 recipients of 
lung, liver, heart, or heart-lung transplants with CKD 
of unknown aetiology were enrolled with the purpose 
of defining the prevalence of BK-related viruria/
viremia, and risk factors associated with BK infection. 
were removed from the list. Of the remaining 19 
articles, 11 studies were identified that specifically 
evaluated the prevalence of BKV infection among 
adult liver transplant recipients. The relevant studies 
involved 490 liver, 498 kidney, 121 heart, 51 lung, 
11 kidney-heart, 8 kidney-pancreas, 5 kidney-liver, 
1 heart-lung and 1 kidney-heart-liver transplant 
recipients. 
RESULTS
Splendiani et al[50] conducted a single-centre prospective 
analysis among 118 consecutive ambulatory patients 
(37 LT and 81 KT) evaluating the prevalence of BKV 
infection activity and potential associations with 
renal dysfunction. They looked for BKV genome by 
urinary PCR. In positive patients, they repeated PCR 
on plasma. Furthermore they considered hepatitis-C 
infection in order to highlight associations with 
renal dysfunction. Mycophenolate mofetil (MMF), 
tacrolimus (TAC), and sirolimus (SRL) were the most 
commonly used immunosuppressive agents. Among 
KT, transplant mean age was 7 years, mean serum 
creatinine level was 1.4 mg/dL, BUN 57 mg/dL, GOT 
18 UI/L, GPT 16 UI/L; 5 recipients showed hepatitis 
C virus (HCV)-positivity. Eleven patients were BKV 
positive on urine and 7 also on plasma; all patients 
were HCV-negative. Among LT, transplant mean age 
was 4 years, mean sCr level was 1.2 mg/dL, BUN 55 
mg/dL, GOT 36 UI/L, GPT 46 UI/L; 13 recipients were 
HCV-positive. Five patients had BKV in their urine 
and only one had BKV viremia. Three of these were 
also HCV-positive. Considering only BKV-positivity, 16 
patients had BKV viruria (5 among liver and 11 among 
kidney recipients) and 8 had BKV viremia as well (1 
and 7 in liver and kidney recipients respectively). All LT 
recipients with BKV viruria had normal renal function 
whereas viruric KT patients had renal dysfunction, 
more severe in case of BKV viremia. 
In another single-centre prospective study Muñoz 
et al[51], investigated the prevalence of BKV replication 
and the association between BKV replication and renal 
function among 156 non-selected recipients of a SOT 
(49 KT, 43 HT and 64 LT). Urine and plasma samples, 
collected about 559 d after transplantation, were 
analysed for BKV by qualitative PCR. Mycophenolate 
acid and TAC were the most commonly used 
immunosuppressive agents. Renal dysfunction (defined 
as sCr level of 1.5 mg/dL) was present in 42% of 
recipients, BKV viruria and viremia in 19% and 6% 
of transplant patients, respectively. Incidence of BKV 
viruria and viremia was significantly higher in KT 
and HT compared to LT patients. Among 9 viremic 
patients (6 KT and 3 HT), 1 heart transplant and all 
KT recipients had elevated levels of sCr at the time of 
detection of viremia. Interestingly when the authors 
investigated the association between BKV replication 
and renal function, they found mean sCr of 1.3 mg/
dL in BKV-negative patients, 1.9 mg/dL in patients 
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Immunosuppressive therapy included cyclosporine, 
TAC, azathioprine, MMF, SRL and prednisone. Five out 
of 34 patients (15%) had BK viruria, but viremia was 
not detected in any patient and no renal biopsy was 
performed during the study period. Polyomavirus BK 
viruria was significantly associated to CMV disease, 
MMF and cyclosporine, and inversely associated to 
TAC. No associations with episodes of rejection were 
found.
Puliyanda et al[37] investigated the predisposition 
to BKV infection by plasma PCR analysis in 173 KT, 
11 kidney-heart, 5 kidney-liver, 3 kidney-pancreas, 
1 kidney-heart-liver, 24 heart and 37 LT patients 
between 3 and 18 mo after transplantation. Among 
KT, immunosuppressive therapy included induction 
with interleukin-2 receptor blockers or Thymoglobulin 
and maintenance with TAC or cyclosporine, MMF 
and prednisone. Antiviral CMV prophylaxis was 
based on ganciclovir or valganciclovir for donor-
positive/recipient-negative patients and acyclovir for 
others. Among HT, induction therapy was based on 
Thymoglobulin or OKT3 while maintenance therapies 
included cyclosporine or TAC, MMF and prednisone. 
Among LT, induction therapy was not often used 
while maintenance therapy was based on TAC and 
prednisone. Four percent of KT, 9.1% of kidney-
heart, 20% of kidney-liver and 2.7% of LT patients 
showed BKV viremia. Nine out of 10 (90%) recipients 
who were BKV positive on plasma were on MMF 
compared to 166/244 (65%) recipients who were 
BKV plasma negative. No significant differences 
were found between cyclosporine or TAC-based 
immunosuppression regimens among patients with or 
without BKV viremia.
In the single-centre, prospective longitudinal study 
by Doucette et al[49], BKV infection and its association 
with renal dysfunction were analysed in 60 patients 
(7 HT, 25 LT, 28 lung transplant recipients). They 
evaluated BKV on urine by quantitative PCR while 
plasma was analysed only if urine was positive. 
Patients with (n = 9) and without (n = 51) BK viruria 
were not significantly different in their baseline 
characteristics. Immunosuppressive therapy was 
also similar in the two groups with about half of 
the patients receiving TAC. In BKV viruric patients 
baseline glomerular filtration rate (GFR) was not 
significantly less than in patients without viruria. In 
both groups, baseline renal dysfunction was mainly 
related to hepatorenal syndrome, diuretic therapy and 
low cardiac output, altogether conditions which could 
potential improve after transplantation. Five out of 
9 patients with BKV viruria had only one episode of 
documented viruria; 1/9 and 3/9 had BK viruria in two 
and three occasions, respectively. The trend of GFR 
was similar in those with and without BKV viruria from 
baseline to 9 mo after transplantation. BKV viruria was 
found in 15% (9/60) of recipients. No patient had BKV 
viremia and no association was found between BKV 
viruria and renal function.
Salama et al[55] performed a cross-sectional 
prevalence study in 41 unselected LT patient looking 
at BKV viruria/viremia prevalence and its association 
with renal function. Immunosuppressive therapy was 
based on cyclosporine, azathioprine, and prednisolone. 
Tacrolimus and MMF were started when more effective 
immunosuppressive therapy was required and CNI 
were decreased in recipients affected by CKD. None 
patients had antibody induction as standard therapy. 
Blood and urine specimens were collected from all 
recipients for BKV viremia, viruria or decoy cells 
recognition. Authors found 24.3% of BKV viruria 
positive patients without any significant difference in 
terms of time after transplantation, renal dysfunction 
and immunosuppressive therapy when compared 
to BKV viruria negative recipients. Decoy cells were 
detected in 4/41 recipients even if none of these 
resulted positive for BKV viruria by PCR. Furthermore, 
no measurable BKV viremia was found in LT patients. 
A condition of moderate CKD was diagnosed in 83%, 
whereas severe CKD was diagnosed in 7% of patients. 
The GFR decline in recipients with BKV viruria was not 
different from those without viruria. No association 
was found between CNI therapy and CKD, though 
CNI was associated with a quicker reduction in GFR 
after one year post-transplantation. In the multivariate 
analysis, pre-transplant renal function, time after 
transplantation, gender, hepatitis status, CNI therapy 
and blood levels, and BKV viruria did not interact with 
the annual GFR modification.
In a prospective longitudinal study, Loeches et 
al[56] described the incidence of BKV infection and its 
association with renal dysfunction in 62 LT patients. 
They analysed urine and plasma samples for BKV by 
qualitative and quantitative PCR. Quantitative analysis 
showed BKV viremia in 11 (18%) and viruria in 13 
(21%) patients. The median BK viral load was 2.01 × 
105 copies/mL in plasma and 7.58 × 106 in urine. The 
authors did not report any significant association with 
age, gender, race and immunosuppressive therapy 
between BKV-negative recipients, viruric and viremic 
patients. Immunosuppressive therapy consisted 
of TAC, MMF and corticosteroids. No differences in 
the rates of diabetes and HCV infection were found. 
Notably, a significant more frequent BKV viremia 
was showed in patients who experienced a rejection 
episode (10.6% vs 40%). The authors found no 
differences in renal function when BKV infection was 
present. In particular, 19 patients (30.6%) had renal 
dysfunction at some time during the follow-up. Viremia 
was found in the first month after transplant in 7 
patients, in the third month in 3 and on day 270 in one 
recipient. No BKV viremia was identified after 1 year 
post-transplant.
Our group[34] first performed a study on the 
evaluation of BKV replication on plasma and urine 
samples, using quantitative PCR, in 20 patients 
with end stage liver disease (ESLD) and listed for 
LT. The assumption was that ESLD patients are 
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immunocompromised and immunosuppression is a 
known cause of BKV reactivation. Of 20 patients one 
(5%) had both viremia and viruria. A second study[57] 
looked at the prevalence of BKV among 31 LT patients 
with CKD in order to assess the possible role of renal 
dysfunction as risk factor for BKV infection in patients 
with ESLD. We recognized 2 groups of patients on 
the basis of the presence of CKD: No CKD group (22; 
71%) and CKD group (9; 29%). We did not show 
significant differences in the baseline characteristics 
of the 2 groups. The prevalence of BKV viremia and 
viruria was 14% (3/22) and 23% (5/22) respectively 
in patients without CKD whereas it was 56% (5/9) and 
12.5% (1/8) respectively in recipients with CKD. 
A summary of all these studies evaluating the 
prevalence of BKV infection among liver transplant 
recipients is reported in Table 1.
CONCLUSION
We identified a total of 11 relevant studies in the 
literature that specifically evaluated the prevalence of 
BKV infection among adult LT recipients. Overall these 
studies included 490 liver, 498 kidney, 121 heart, 51 
lung, 11 kidney-heart, 8 kidney-pancreas, 5 kidney-
liver, 1 heart-lung and 1 kidney-heart-liver transplant 
recipients. Our review suggests that the prevalence 
of BKV viruria and/or viremia among LT patients is 
less than that reported in KT or HT recipients, except 
when CKD is present at the same time. Data also 
suggest that viruric and viremic patients have higher 
levels of sCr than BKV-negative patients. Moreover, 
though KT recipients are usually exposed to higher 
levels of immunosuppression, the anti-rejection drugs 
used are similar to those prescribed in liver or heart 
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Table 1  Summary of studies evaluating the prevalence of BK virus infection among liver transplant recipients  n  (%)
Ref. Organ n Study Design Viruria Viremia
Splendiani et al[50] Liver 37 Single-centre 
prospective 
analysis
  5 (13.5) 1 (2.7)
Kidney 81 11 (13.6) 7 (8.6)
Total 118 
Muñoz et al[51] Liver 64 Prospective 
prevalence 
study
5 (7.8) 0 (0)
Kidney 49 13 (26.5)      6 (12.2)
Heart 43 11 (25.6)    3 (7.0)
Total 156
Randhawa et al[52] Liver 44 Cross-sectional 
study
  7 (15.9) 0 (0)
Kidney 103 36 (34.9)    8 (7.7)
Total 147
Razonable et al[53] Liver 121 Longitudinal 
surveillance 
study
No urine 
 analysis
  5 (4.1)
Kidney 92   24 (26.1)
Heart 45   3 (6.7)
Kidney-pancreas   5 0 (0)
Total 263
Barton et al[54] Liver   8 Prospective, 
single-centre, 
cross-sectional study
0 (0) 0 (0)
Heart   2      1 (50.0) 0 (0)
Lung 23      4 (17.4) 0 (0)
Heart-lung   1 0 (0) 0 (0)
Total 34
Puliyanda et al[37] Liver   37 Single centre,
 prospective 
study
No urine
 analysis
   1 (2.7)
Kidney 173    7 (4.0)
Kidney-liver     5      1 (20.0)
Heart   24 0 (0)
Kidney-heart   11   1 (9.1)
Kidney-pancreas     3 0 (0)
Kidney-heart-liver     1 0 (0)
Total 254
Doucette et al[49] Liver   25 Single centre,
 prospective 
longitudinal 
study
3 (12) 0 (0)
Heart     7   1 (14.3) 0 (0)
Lung   28   5 (17.8) 0 (0)
Total 60
Salama et al[55] Liver   41 
Total 41
Cross-sectional point 
prevalence study
10 (24.4) 0 (0)
Loeches et al[56] Liver   62 
Total 62
Prospective 
longitudinal study
13 (21.0)    11 (18.0)
Mitterhofer et al[34] Liver   20 
Total 20
Single-centre 
prospective study
1 (5.0)    1 (5.0)
Mitterhofer et al[57] Liver plus     9 Single-centre 
prospective 
study
  1 (11.1)     5 (55.5)
 CKD   22   5 (23.0)     3 (13.6)
Liver no CKD Total 31
CKD: Chronic kidney disease.
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transplantation and no specific immunosuppressive 
drugs are associated with the onset of PVAN. 
The higher prevalence of BKV infection among 
KT recipients could have other explanations. Chronic 
kidney disease seems to represent a risk factor 
for BKV replication. Immunosuppression is recog-
nised as the major cause of BKV replication and 
patients affected by CKD are considered immuno-
compromised[57]. The immune system controlling BKV 
infection requires the production and the activation of 
specific antibody, antigen-presenting cells (APC), 
and cytotoxic T-cells[58]. Patients who develop CKD 
have disorders of acquired immunity related mainly 
to the function of T-lymphocytes and APC. As a 
result, patients may be susceptible to viral infections 
and show deficient responses to vaccinations. 
Furthermore, KT patients have disturbances of 
viral-specific immunity, as revealed by functional 
deterioration of dendritic and cytotoxic T-cells. These 
alterations may clarify the higher prevalence of PVAN 
identified in this population[57]. On the contrary, liver 
immunodysfunction is characterised by impairment 
of the antibacterial rather than antiviral immunity, 
with amplified apoptosis, activation of T-cells and 
monocytes, and macrophagic dysfunction responsible 
for microorganism’s opsonisation and elimination[57]. 
In support of this different immunological mechanism 
no case of PVAN is reported among liver transplant 
patients. Nevertheless, CKD in LT could be a risk 
factor for BKV infection in this particular population. 
In fact Mitterhofer et al[57] showed a significant higher 
prevalence of BKV infection in plasma of ESLD patients 
with CKD prior to LT, whereas in LT recipients without 
CKD the prevalence was similar to normal subjects. 
Therefore, renal dysfunction in LT may be an additional 
factor causing immunologic dysfunction that could 
make patients more susceptible to infections. Thus, 
the transplant-associated comorbidity and CKD 
could promote BKV replication in plasma. This could 
represent an attractive explanation regarding the 
mechanisms involved in the different behaviour of BKV 
infection in LT recipients. Further studies will be needed 
to better identify the risk factors for BKV replication in 
NRSOT.
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